1. Home
  2. FNWD vs KLRS Comparison

FNWD vs KLRS Comparison

Compare FNWD & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Finward Bancorp

FNWD

Finward Bancorp

HOLD

Current Price

$33.39

Market Cap

164.2M

Sector

Finance

ML Signal

HOLD

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

N/A

Current Price

$6.30

Market Cap

144.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FNWD
KLRS
Founded
1994
2019
Country
United States
United States
Employees
N/A
20
Industry
Savings Institutions
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
164.2M
144.9M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
FNWD
KLRS
Price
$33.39
$6.30
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$37.50
$19.00
AVG Volume (30 Days)
2.8K
80.5K
Earning Date
04-24-2026
05-13-2026
Dividend Yield
1.48%
N/A
EPS Growth
N/A
N/A
EPS
1.88
N/A
Revenue
N/A
N/A
Revenue This Year
$17.40
N/A
Revenue Next Year
$5.44
N/A
P/E Ratio
$17.06
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.46
$2.14
52 Week High
$39.99
$11.88

Technical Indicators

Market Signals
Indicator
FNWD
KLRS
Relative Strength Index (RSI) 37.77 43.62
Support Level $31.52 $5.26
Resistance Level $38.79 $7.18
Average True Range (ATR) 0.75 0.59
MACD -0.17 0.15
Stochastic Oscillator 52.17 47.09

Price Performance

Historical Comparison
FNWD
KLRS

About FNWD Finward Bancorp

Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Share on Social Networks: